USD $495.50
IndiaAcabrunat, also known as Acalabrutinib, is a targeted therapy used primarily in the treatment of certain types of blood cancers, particularly chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). It is a selective Bruton’s tyrosine kinase (BTK) inhibitor that works by blocking signals that lead to the growth and survival of cancer cells.
By inhibiting BTK, Acabrunat disrupts the signaling pathways necessary for the proliferation and survival of malignant B cells. This targeted approach helps to minimize damage to normal cells, leading to potentially fewer side effects compared to traditional chemotherapy.
Acabrunat is indicated for the treatment of:
This medication is typically taken orally, with or without food. It is important to follow the prescribed dosage and schedule provided by your healthcare provider to ensure optimal effectiveness.
Common side effects of Acabrunat may include:
Patients should report any severe or persistent side effects to their healthcare provider.
Before starting Acabrunat, it is essential to inform your doctor of any existing medical conditions, especially heart problems or bleeding disorders. Regular monitoring may be required during treatment.
Acabrunat represents a significant advancement in the targeted treatment of specific blood cancers, offering hope for improved outcomes with a favorable side effect profile. Always consult with your healthcare provider for personalized medical advice and treatment plans.
